Climb Bio (CLYM) vs Ironwood Pharmaceuticals (IRWD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Climb Bio (CLYM) has outperformed Ironwood Pharmaceuticals (IRWD) over the past year, gaining 503.3% versus a gain of 144.9%. Over five years, CLYM leads with a -32.7% price change compared with -71.7% for IRWD. Ironwood Pharmaceuticals is the larger company by market cap ($650.2 million vs $637.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLYM | IRWD |
|---|---|---|
| Share price | $11.10 | $3.94 |
| Market cap | $637.54M | $650.22M |
| 1-day change | +2.21% | +1.68% |
| YTD return | +171.50% | +14.84% |
| 1-year return | +503.33% | +144.94% |
| 5-year return | -32.71% | -71.67% |
| P/E ratio (TTM) | — | 5.11 |
| Forward P/E | — | 2.62 |
| EPS (TTM) | $-0.82 | $0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.33 | $5.78 |
| 52-week low | $1.64 | $1.41 |
| Distance from 52-week high | -39.44% | -31.92% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +148.38% | +55.02% |
| Average volume | 1.37M | 2.02M |
| Shares outstanding | 57.44M | 165.24M |
| Employees | 28 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed IRWD by 358.4 percentage points over the past year.
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
CLYM vs IRWD FAQ
Which is bigger, Climb Bio or Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals (IRWD) is larger, with a market capitalization of $650.22M compared with $637.54M for Climb Bio (CLYM).
Which stock has performed better over the past year, CLYM or IRWD?
CLYM returned +503.33% over the past 12 months, compared with +144.94% for IRWD (price return, excluding dividends). Past performance does not predict future results.
Are Climb Bio and Ironwood Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.